AR008555A1 - Constructo de acido nucleico para expresar sustancias activas que son activadas por una enzima que es liberada por celulas de mamifero, unprocedimiento para preparar un constructo de acido nucleico, el uso para preparar su farmaco, una celula alterada por medios recombinantes y una - Google Patents
Constructo de acido nucleico para expresar sustancias activas que son activadas por una enzima que es liberada por celulas de mamifero, unprocedimiento para preparar un constructo de acido nucleico, el uso para preparar su farmaco, una celula alterada por medios recombinantes y unaInfo
- Publication number
- AR008555A1 AR008555A1 ARP980100164A ARP980100164A AR008555A1 AR 008555 A1 AR008555 A1 AR 008555A1 AR P980100164 A ARP980100164 A AR P980100164A AR P980100164 A ARP980100164 A AR P980100164A AR 008555 A1 AR008555 A1 AR 008555A1
- Authority
- AR
- Argentina
- Prior art keywords
- nucleic acid
- acid construct
- enzyme
- released
- protein
- Prior art date
Links
- 108020004707 nucleic acids Proteins 0.000 title abstract 6
- 102000039446 nucleic acids Human genes 0.000 title abstract 6
- 150000007523 nucleic acids Chemical class 0.000 title abstract 6
- 102000004190 Enzymes Human genes 0.000 title abstract 3
- 108090000790 Enzymes Proteins 0.000 title abstract 3
- 210000004027 cell Anatomy 0.000 title abstract 3
- 210000004962 mammalian cell Anatomy 0.000 title abstract 3
- 239000013543 active substance Substances 0.000 title abstract 2
- 108010042653 IgA receptor Proteins 0.000 abstract 3
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 3
- 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6432—Coagulation factor Xa (3.4.21.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21006—Coagulation factor Xa (3.4.21.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/007—Vector systems having a special element relevant for transcription cell cycle specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Un constructo se refiere a un constructo de ácido nucleico para expresar una sustancia activa que es activada por una enzima que es liberadapor célulasde mamífero, comprendiendo el constructo los componentes siguientes: a) al menos unelement o promotor, b) al menos una secuencia de ADN que codifica uncompuesto activo (proteína B); c) al menos una secuencia de ADN que codifica una secuencia de aminoácidos (estructura parcial C) que puede ser escindidaespecíficamente por unaenzima que es liberada por una célula de mamífero, y d) al menos una secuencia de ADN que codifica un péptido o proteína (estructuraparcial D) que está unida al compuesto activo (proteína B) por la vía de la secuencia de aminoácidosescindible (estructu ra parcial C) e inhibe laactividad del compuesto activo (proteína B), y también al procedimiento para preparar un constructo de ácido nucleico, al uso para preparar un fármaco, unacélula alterada por medios recombinantes yuna proteína que es codi ficada por dicho constructo de ácido nucleico y una célula que aloja un constructo deácido nucleico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19701141A DE19701141C1 (de) | 1997-01-16 | 1997-01-16 | Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen |
Publications (1)
Publication Number | Publication Date |
---|---|
AR008555A1 true AR008555A1 (es) | 2000-01-19 |
Family
ID=7817422
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP980100164A AR008555A1 (es) | 1997-01-16 | 1998-01-14 | Constructo de acido nucleico para expresar sustancias activas que son activadas por una enzima que es liberada por celulas de mamifero, unprocedimiento para preparar un constructo de acido nucleico, el uso para preparar su farmaco, una celula alterada por medios recombinantes y una |
Country Status (15)
Country | Link |
---|---|
US (3) | US6080575A (es) |
EP (1) | EP0859058A3 (es) |
JP (1) | JPH10210973A (es) |
KR (1) | KR19980070549A (es) |
CN (1) | CN1192473A (es) |
AR (1) | AR008555A1 (es) |
AU (1) | AU738717B2 (es) |
BR (1) | BR9800341A (es) |
CA (1) | CA2227159A1 (es) |
CZ (1) | CZ13298A3 (es) |
DE (1) | DE19701141C1 (es) |
HU (1) | HUP9800075A3 (es) |
PL (1) | PL324328A1 (es) |
RU (1) | RU2204414C2 (es) |
TR (1) | TR199800046A2 (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10039844A1 (de) * | 1999-08-10 | 2001-04-19 | Hepavec Ag Fuer Gentherapie | Kombinationsvektoren für den Gentransfer, Verfahren zu ihrer Herstellung und ihre Verwendung |
EP1283719B1 (de) * | 2000-04-22 | 2007-09-05 | PharmedArtis GmbH | Apoptotika |
WO2002020715A2 (en) * | 2000-09-05 | 2002-03-14 | Biosight Ltd. | Peptide conjugated anti-cancer prodrugs |
US8314060B2 (en) | 2000-09-05 | 2012-11-20 | Biosight Ltd. | Peptide conjugated anti-cancer prodrugs |
US7273722B2 (en) * | 2000-11-29 | 2007-09-25 | Allergan, Inc. | Neurotoxins with enhanced target specificity |
US7041787B2 (en) * | 2000-12-29 | 2006-05-09 | Kimberly-Clark Worldwide, Inc. | Design and use of advanced zinc chelating peptides to regulate matrix metalloproteinases |
US6600057B2 (en) | 2000-12-29 | 2003-07-29 | Kimberly-Clark Worldwide, Inc. | Matrix metalloproteinase inhibitors |
US7141392B2 (en) * | 2001-01-09 | 2006-11-28 | Queen Mary And Westfield College | Latent fusion protein |
US6942853B2 (en) * | 2001-01-09 | 2005-09-13 | Queen Mary And Westfield College | Latent fusion protein |
GB0105929D0 (en) * | 2001-03-09 | 2001-04-25 | Btg Int Ltd | Physiologically activated prodrugs |
EP1385994A2 (de) * | 2001-04-02 | 2004-02-04 | Bayer HealthCare AG | Verfahren zur spezifischen detektion, isolation und charakterisierung von zellen aus körperproben durch transfektion von nukleinsäurekonstrukten |
US7247618B2 (en) | 2001-04-30 | 2007-07-24 | Tripathi Rajavashisth | Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling |
US20030157641A1 (en) * | 2001-11-16 | 2003-08-21 | Idec Pharmaceuticals Corporation | Polycistronic expression of antibodies |
WO2003051393A2 (en) * | 2001-12-17 | 2003-06-26 | University Of Wales College Of Medicine | Enzymatic cleavable reagents for specific delivery to disease sites |
US20030119073A1 (en) * | 2001-12-21 | 2003-06-26 | Stephen Quirk | Sensors and methods of detection for proteinase enzymes |
AU2003217415B2 (en) * | 2002-02-14 | 2009-01-08 | William J Rutter | Chimeric molecules for cleavage in a treated host |
CN1780920B (zh) * | 2003-05-12 | 2012-03-28 | 波多玛克制药有限公司 | 基因表达抑制剂 |
EP1639097B1 (en) * | 2003-06-25 | 2013-08-07 | Ottawa Health Research Institute | Methods and compositions for modulating stem cell growth and differentiation |
US20060153797A1 (en) * | 2004-06-11 | 2006-07-13 | Bortolotto Susan K | Tissue material and matrix |
KR100604976B1 (ko) * | 2004-09-03 | 2006-07-28 | 학교법인연세대학교 | 다작용기 리간드로 안정화된 수용성 나노입자 |
WO2008013918A2 (en) * | 2006-07-26 | 2008-01-31 | Myelin Repair Foundation, Inc. | Cell cycle regulation and differentiation |
BRPI0721630A2 (pt) | 2007-05-02 | 2013-10-15 | Merial Ltd | Plasmídeo de dna tendo expressão e estabilidade aperfeiçoadas |
WO2008156789A2 (en) * | 2007-06-15 | 2008-12-24 | The Scripps Research Institute | Methods and compositions for identifying binding partners from libraries of biomolecules |
GB0800272D0 (en) * | 2008-01-08 | 2008-02-13 | Plant Bioscience Ltd | Protein expression systems |
EP3543256A1 (en) | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
WO2011123683A2 (en) * | 2010-04-02 | 2011-10-06 | University Of Rochester | Protease activated cytokines |
EP2628748A1 (en) | 2012-02-14 | 2013-08-21 | Szilak Laboratories Bioinformatics & Molecule-Design Ltd. | Angiostatin chimeras and uses thereof |
WO2014018120A1 (en) | 2012-07-25 | 2014-01-30 | Catalyst Biosciences, Inc. | Modified factor x polypeptides and uses thereof |
MA40094B1 (fr) * | 2014-08-06 | 2022-05-31 | Univ Miami | Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation |
AU2019271148B2 (en) | 2018-05-14 | 2023-07-06 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
MX2020012252A (es) | 2018-05-14 | 2021-04-28 | Werewolf Therapeutics Inc | Polipeptidos de interleucina 12 activables y metodos de uso de los mismos. |
CA3137512A1 (en) | 2019-05-14 | 2020-11-19 | Werewolf Therapeutics, Inc. | Separation moieties and methods and use thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4228457A1 (de) * | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
DE19524720A1 (de) | 1995-07-12 | 1997-01-16 | Hoechst Ag | Zellspezifische Gentherapie mit Hilfe eines neuen Promotors für den "Tissue Inhibitor of Metalloproteinasn-3" |
SE9403613D0 (sv) | 1994-10-21 | 1994-10-21 | Pharmacia Ab | Improvement of an expression vector for production of recombinant proteins |
AU4608296A (en) * | 1994-12-30 | 1996-07-31 | Chiron Corporation | Methods and compositions for treatment of solid tumors in vivo |
US5726050A (en) | 1995-06-20 | 1998-03-10 | Massachusetts Institute Of Technology | Z-DNA binding protein and applications |
JPH11509088A (ja) | 1995-06-23 | 1999-08-17 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 血管内皮増殖因子受容体をコードする遺伝子の転写調節 |
DE19605274A1 (de) | 1996-02-13 | 1997-08-14 | Hoechst Ag | Nukleinsäurekonstrukte für die zellzyklusregulierte Expression von Genen, derartige Konstrukte enthaltende Zellen sowie deren Verwendung zur Herstellung von Heilmitteln |
DE19605279A1 (de) | 1996-02-13 | 1997-08-14 | Hoechst Ag | Zielzellspezifische Vektoren für die Einschleusung von Genen in Zellen, Arzneimittel enthaltend derartige Vektoren und deren Verwendung |
EP0941334B1 (en) * | 1996-11-06 | 2004-06-02 | THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services | Protease-activatable pseudomonas exotoxin a-like proproteins |
-
1997
- 1997-01-16 DE DE19701141A patent/DE19701141C1/de not_active Expired - Fee Related
-
1998
- 1998-01-14 CZ CZ98132A patent/CZ13298A3/cs unknown
- 1998-01-14 TR TR1998/00046A patent/TR199800046A2/xx unknown
- 1998-01-14 AR ARP980100164A patent/AR008555A1/es unknown
- 1998-01-14 CN CN98103791A patent/CN1192473A/zh active Pending
- 1998-01-15 EP EP98100632A patent/EP0859058A3/de not_active Withdrawn
- 1998-01-15 RU RU98100678/14A patent/RU2204414C2/ru not_active IP Right Cessation
- 1998-01-15 HU HU9800075A patent/HUP9800075A3/hu unknown
- 1998-01-16 US US09/008,308 patent/US6080575A/en not_active Expired - Lifetime
- 1998-01-16 KR KR1019980001096A patent/KR19980070549A/ko not_active Application Discontinuation
- 1998-01-16 BR BR9800341A patent/BR9800341A/pt not_active IP Right Cessation
- 1998-01-16 AU AU52107/98A patent/AU738717B2/en not_active Ceased
- 1998-01-16 PL PL98324328A patent/PL324328A1/xx unknown
- 1998-01-16 JP JP10006589A patent/JPH10210973A/ja active Pending
- 1998-01-16 CA CA002227159A patent/CA2227159A1/en not_active Abandoned
-
1999
- 1999-02-24 US US09/256,237 patent/US6670147B1/en not_active Expired - Lifetime
-
2003
- 2003-08-12 US US10/638,537 patent/US20040110682A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
TR199800046A3 (tr) | 1998-10-21 |
PL324328A1 (en) | 1998-07-20 |
HUP9800075A3 (en) | 2004-03-29 |
KR19980070549A (ko) | 1998-10-26 |
CN1192473A (zh) | 1998-09-09 |
DE19701141C1 (de) | 1998-04-09 |
US20040110682A1 (en) | 2004-06-10 |
CZ13298A3 (cs) | 1998-08-12 |
EP0859058A2 (de) | 1998-08-19 |
EP0859058A3 (de) | 2003-05-28 |
JPH10210973A (ja) | 1998-08-11 |
US6080575A (en) | 2000-06-27 |
HUP9800075A2 (hu) | 1998-10-28 |
RU2204414C2 (ru) | 2003-05-20 |
CA2227159A1 (en) | 1998-07-16 |
US6670147B1 (en) | 2003-12-30 |
TR199800046A2 (xx) | 1998-10-21 |
BR9800341A (pt) | 1999-06-29 |
AU738717B2 (en) | 2001-09-27 |
AU5210798A (en) | 1998-07-23 |
HU9800075D0 (en) | 1998-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR008555A1 (es) | Constructo de acido nucleico para expresar sustancias activas que son activadas por una enzima que es liberada por celulas de mamifero, unprocedimiento para preparar un constructo de acido nucleico, el uso para preparar su farmaco, una celula alterada por medios recombinantes y una | |
AR016537A1 (es) | Una celula humana para la fabricacion de eritropoyetina por activacion genica endogena, un procedimiento para la fabricacion de la misma y una construccionde adn a ser usada en el mismo, un procedimiento para la fabricacion de epo humana, epo humana aislada obtenida por el mismo y un preparado farma | |
Grant et al. | Amino acid sequence of a collagenolytic protease from the hepatopancreas of the fiddler crab, Uca pugilator | |
AR035786A2 (es) | Variantes de factores de coagulacion dependientes de vitamina k y composiciones que los contienen | |
WO2002031134A3 (en) | Novel serine protease genes related to dppiv | |
ES2163864T3 (es) | Secuencias de dna de 2-desoxiglucosa-6-fosfato (2-dog-6-p) como marcador de seleccion en plantas. | |
DE50015518D1 (de) | vERFAHREN ZUR VERRINGERUNG DER ANTIGENITÄT DES ADENO-ASSOZIIERTEN VIRUS STRUKTURPROTEINS | |
ATE92105T1 (de) | Expression von faktor-vii-aktivitaet in saeugetierzellen. | |
DE69637874D1 (de) | C-C CHEMOKIN REZEPTOR 3: CKR-3 ODER Eos-L2 | |
Grant et al. | Biosynthesis of an insulin precursor by islet tissue of cod (Gadus callarias) | |
BR9713108A (pt) | Colagenase recombinante do tipo i de clostridium histolytucum e o uso da mesma para o isolamento de células e de grupos de células | |
MC2144A1 (fr) | Peptides therapeutiques | |
ES2144394T3 (es) | Polipeptidos y peptidos recombinantes, acidos nucleicos que los codifican y utilizacion de dichos polipeptidos y peptidos para el diagnostico de la tuberculosis. | |
AR023482A1 (es) | Acidos nucleicos que codifican polipeptidos quimericos cd40/cd4ol, metodos para su produccion y usos de los mismos | |
AR010341A1 (es) | Constructo de acido nucleico farmacologicamente controlable auto- intensificante, proceso para preparar dicho constructo, vector y celula que locomprenden y uso del mismo y una composicion farmaceutica que comprende el constructo de acido nucleico y un metodo para preparar la composicion | |
ATE293169T1 (de) | Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen | |
DE3751632D1 (de) | Expression von biologisch-aktiven PDGF-Analogen in eukaryotischen Zellen | |
Bab et al. | Isolation of mitogenically active C‐terminal truncated pentapeptide of osteogenic growth peptide from human plasma and culture medium of murine osteoblastic cells | |
ES2054612T3 (es) | Secuencias de adn que codifican para proteinas con actividad biologica de los inhibidores husi tipo-i y procedimientos tecnologicos geneticos para la preparacion de estas proteinas. | |
DE60039677D1 (de) | Akt-3 nukleinsäure, polypeptide und deren verwendung | |
AR012499A1 (es) | Una secuencia quimerica de acido nucleico que codifica una proteina de fusion, un vector de expresion que comprende dicha secuencia quimerica, una celula huesped transformada que contiene dicho vector, la proteina de fusion obtenida y un metodo in vitro para la preparacion de un polipeptido recombin | |
AR011458A1 (es) | Promotor del gen cdc25b, construccion de acido nucleico que comprende dicho promotor, proceso para encontrar y aislar dicho promotor, proceso parapreparar dicha construccion, celula que alberga dicha construccion y uso de dicha construccion para preparar un farmaco | |
EA200000202A1 (ru) | Рекомбинантная экспрессия c-пептида инсулина | |
ATE464320T1 (de) | Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk) | |
ES2086402T3 (es) | Codificacion de adn para una proteina capaz de unirse al potenciador del gen de la alfa-fetoproteina. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |